Biomarkers are becoming valuable assistants for predicting prognosis and dose selection in personalized medicine. Moreover, they help detect therapeutic and adverse responses and stratify patients based on efficacy or safety prediction. They are essential tools for the selection of appropriate patients for treatment to enable personalized medicine. Their usage in melanoma and systemic sclerosis has significantly improved the treatment trajectory providing patients with the right dose at the right time.
The global biomarkers market size was valued at $46.4 billion in 2023, and is projected to reach $134.2 billion by 2033, growing at a CAGR of 11.2% from 2024 to 2033. Rise in adoption of biomarkers for drug development and discovery and rise in prevalence of chronic diseases are expected to drive the growth of the biomarkers market.
Applications in melanoma and improvement of histopathologic diagnosis
Biomarkers are well established in dermato-oncology, and their use goes far beyond that of the approved stratification biomarkers for drugs. Prognostic biomarkers are of particular importance regarding this matter. One of the oldest and most important prognostic biomarkers in melanoma is tumor thickness. Another example is the expression level of the nuclear cell proliferation factor Ki-67. Tumor-infiltrating lymphocytes and CD2 count correlate closely with survival in ulcerated melanomas. Blood tests of tumor marker protein S100 beta are used to indicate disease progression in melanoma. In contrast to progression-free survival, no molecular biomarker is regarded as a strong surrogate for overall survival. Using highly sensitive assays, KIT D816V is detected in peripheral blood leucocytes from most patients with systemic mastocytosis. This is a major step forward in screening and early diagnosis of the disease. Active nuclear IKK correlates with metastatic risk of cutaneous squamous cell carcinoma.
Despite recent advances with the expansion of the use of immune checkpoint inhibitors, melanoma continues to confer significant morbidity and mortality. In 2024, 200,340 cases of melanoma are projected to be diagnosed. In January 2023, the FDA approved a new diagnostic test that detects Ki-67 expression levels in melanoma patients. This test helps clinicians assess tumor proliferation and make more informed treatment decisions based on prognosis. In Europe, on average, melanoma treatment costs up to ten thousand Euros per patient on average, and these costs are expected to increase with the wider adoption of immune checkpoint inhibitors and targeted kinase inhibitors. The four instances where biomarkers have proven to have reduced uncertainties in the investigation are deciding whether to biopsy a melanocytic neoplasm, confirming a histopathologic diagnosis, stratifying risk for lymphatic spread with consideration for SLNB, and selecting systemic therapy.
Facilitating understanding of genetic mechanisms in systemic sclerosis
Human autoimmune diseases are complicated and highly diverse conditions of a localized or systemic nature. Understanding the basic biology of autoimmune diseases goes hand in hand with providing clinics with valuable biomarkers for managing these diseases. In the last few years, several new biomarkers have been suggested, many provided with modern genomic studies. This includes epigenetic regulation of DNA, RNA transcriptomics, and regulatory RNA such as microRNA and long non-coding RNA. These findings shed light on the genetic mechanisms behind the disease and contribute to improved diagnosis and treatment.
Systemic sclerosis is an autoimmune inflammatory disorder of unknown etiology characterized by pronounced fibroproliferative alterations in the microvasculature and frequent cellular and humoral immunity abnormalities. This culminates in a severe and often progressive fibrotic process. Numerous biomarkers reflecting the three main pathogenetic mechanisms in systemic sclerosis have been described; however, aside from several disease-specific autoantibodies, other biomarkers have not been thoroughly validated and require further study. Thus, there is an unmet need for validated biomarkers for diagnosis, disease classification, and evaluation of organ involvement and therapeutic response in systemic sclerosis. The clinical semi-quantitative assessment of skin thickness is currently the standard, and the only outcome measure used in clinical trials of SSc disease-modifying agents.
Biomarkers for SSc are categorized based on how they assist in the diagnosis to determine clear clinical subsets that have specific patterns of organ involvement, evolution. It is also based on the prediction of specific organ involvement such as tissue fibrosis or vascular alterations. Other biomarkers allow investigation of disease activity, including forecasting the clinical course or mortality, or determining the effectiveness of a therapeutic intervention. This group of biomarkers is also often used as endpoints in the clinical trials of potential interventions or treatments. The applications of biomarkers such as S100, Ki-67, HMB-45, anti-Scl-70 antibodies and serum levels of Krebs von den Lungen-6 has facilitated earlier detection and treatment, which is important for improving patient outcomes.
The integration of liquid biomarkers, such as circulating tumor DNA and RNA, is also enhancing diagnostic capabilities, making it easier to monitor disease progression and treatment response. The identification of these biomarkers aids in early diagnosis and better management strategies, increasing the demand for diagnostic tests in clinical settings. The growing focus on biomarker discovery is leading to increased investment in R&D within the pharmaceutical and biotechnology sectors. Moreover, companies are investing in innovative biomarker technologies to develop companion diagnostics that predict patient responses to targeted oncology therapies. As awareness increases regarding the importance of early detection and personalized treatment plans, healthcare providers are more inclined to adopt biomarker testing. These factors are significantly boosting the global biomarkers market. The industry is expected to garner a revenue of $134.2 billion by 2033.
The bottom line
Biomarkers have enabled precise prognosis and treatment decisions. They have ensured that patients receive the required therapy on time. The advancements in diagnostic tests and the integration of liquid biomarkers are also improving early detection and monitoring of diseases, which is important for enhancing patient outcomes. Investments in R&D have significantly increased with discoveries of biomarkers paving the way for innovative solutions that improve patient responses to treatment. This change is expected to positively impact healthcare, making treatment plans more accessible and effective.
✍ **𝑨𝒓𝒕𝒊𝒄𝒍𝒆 𝒘𝒓𝒊𝒕𝒆𝒓: Saranya Ganguly
Author’s Bio:
Saranya Ganguly is a B2B writer with extensive experience in crafting research-driven content.
The knack for blending insights and statistics with creative flair motivates her to deliver engaging, and impactful write-ups. She specializes in web articles, newsletters, promotional pieces, and LinkedIn briefs, helping businesses articulate their brand voice and value propositions. A master's degree holder in English and Commonwealth Literature, Saranya enjoys reading in her free time. When not writing, she dabbles in photography and fine art.
0 Comments